Flow cytometry market worth USD 7.0 billion by 2028

In the near future, the flow cytometry industry is poised to undergo remarkable advancements, driven by ongoing innovations in technology and its widening applications across various fields. With the integration of artificial intelligence and machine learning, data analysis and interpretation will become more efficient and accurate, enabling researchers and clinicians to gain deeper insights from complex cellular data. The miniaturization of flow cytometry instruments will lead to portable and point-of-care devices, revolutionizing diagnostics and personalized medicine. Additionally, the incorporation of multi-parameter analysis and higher-throughput capabilities will enhance the speed and comprehensiveness of cellular profiling. As the industry continues to evolve, collaborations between academia, industry, and healthcare will play a pivotal role in shaping the future of flow cytometry, unlocking its potential to uncover novel discoveries and improve patient outcomes.

Flow cytometry market in terms of revenue was estimated to be worth $4.7 billion in 2023 and is poised to reach $7.0 billion by 2028, growing at a CAGR of 8.3% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The growth of this market is driven by the increasing prevalence of chronic diseases and increasing funding for research. Moreover, the launch of novel products in the market by key market players and increased use of flow cytometry in clinical research & diagnostics, such as HIV/AIDS Monitoring, organ transplantation, and cancer diagnostics, are some of the elements propelling the growth of the market.

The ragents & consumables segment accounted for the largest share of the product & service segment in the flow cytometry market in 2022
Based on products & services, the flow cytometry market is segmented into software, services, reagents & consumables, instruments, and accessories. Reagents & consumables accounted for the largest share of the flow cytometry market in 2022. The factors attributable to the growth, development of high-quality reagents, increased research activities, and launch of application-specific cytometry reagents.

The research application segment accounted for the largest share of the application segment in the flow cytometry market in 2022
Based on applications, the flow cytometry market is segmented into clinical, research and industrial applications. In 2022, the research applications segment accounted for the dominant share in the global flow cytometry market. The dominance of the market is attributable to various factors, such as increased research activities & funding and a rise in industrial & academic collaboration. The clinical applications segment is likely to grow at a significant CAGR owing to the increased adoption of flow cytometry in clinical applications.

North America dominated the flow cytometry market in 2022
Based on region, the flow cytometry market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. In 2022, North America dominated the market, followed by Europe. The presence of key market players in the region and increasing public-private initiatives for research activities are key factors supporting the growth of the North American flow cytometry market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high prevalence of HIV/AIDS & cancer and rising treatment options for target diseases (cancer and immunological disorders) are driving the market growth. Further factors like rising government funding and the strong presence of key players in the region are some of the factors anticipated to contribute to the flow cytometry market growth in the Asia Pacific.

Key market players:
Key players in the flow cytometry market include BD (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Sony Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux (France), Cytonome/ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences (US), Union Biometrica, Inc. (US), Luminex Corporation (Italy), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), (US), Nexcelom Biosciences LLC. (US), BennuBio Inc. (US), Orflo Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands). MarketsandMarkets™